MTM1 and X-linked myotubular myopathy: In particular, recent examples of engineered forms of PTPs have been used to improve target delivery to specific cellular compartments [15], as replacement therapy to improve muscle weakness in Myotubularin knock out mice with symptoms of XLMTM [16], or to increase tumour suppressor activity of PTEN [17, 18].